Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

May 10, 2024

SELL
$1.1 - $2.45 $59,789 - $133,167
-54,354 Reduced 71.28%
21,900 $27,000
Q4 2022

Jun 14, 2023

BUY
$1.1 - $2.45 $24,090 - $53,655
21,900 New
21,900 $27.2 Million
Q3 2022

May 10, 2024

BUY
$1.96 - $3.32 $55,973 - $94,812
28,558 Added 59.88%
76,254 $157,000
Q3 2022

Jun 14, 2023

BUY
$1.96 - $3.32 $149,457 - $253,163
76,254 New
76,254 $157 Million
Q2 2022

May 10, 2024

SELL
$2.27 - $4.86 $21,254 - $45,504
-9,363 Reduced 16.41%
47,696 $132,000
Q2 2022

Jun 20, 2023

BUY
$2.27 - $4.86 $108,269 - $231,802
47,696 New
47,696 $132 Million
Q1 2022

May 10, 2024

BUY
$3.69 - $5.65 $210,547 - $322,383
57,059 New
57,059 $249,000
Q1 2022

Jun 20, 2023

BUY
$3.69 - $5.65 $210,547 - $322,383
57,059 New
57,059 $249 Million
Q4 2021

May 17, 2024

SELL
$5.37 - $7.07 $76,474 - $100,683
-14,241 Reduced 34.21%
27,391 $151,000
Q4 2021

Jun 21, 2023

BUY
$5.37 - $7.07 $147,089 - $193,654
27,391 New
27,391 $151 Million
Q3 2021

May 17, 2024

BUY
$5.54 - $7.51 $61,438 - $83,285
11,090 Added 36.31%
41,632 $257,000
Q3 2021

Jun 21, 2023

BUY
$5.54 - $7.51 $230,641 - $312,656
41,632 New
41,632 $257 Million
Q2 2021

May 17, 2024

SELL
$7.78 - $11.4 $111,199 - $162,940
-14,293 Reduced 31.88%
30,542 $259,000
Q1 2021

May 17, 2024

BUY
$5.12 - $8.48 $229,555 - $380,200
44,835 New
44,835 $354,000
Q1 2021

Jun 26, 2023

BUY
$5.12 - $8.48 $229,555 - $380,200
44,835 New
44,835 $355 Million
Q4 2020

May 24, 2024

BUY
$3.16 - $7.03 $35,471 - $78,911
11,225 Added 93.15%
23,276 $135,000
Q4 2020

Jun 22, 2023

BUY
$3.16 - $7.03 $73,552 - $163,630
23,276 New
23,276 $135 Million
Q3 2020

May 24, 2024

SELL
$3.26 - $4.73 $77,662 - $112,682
-23,823 Reduced 66.41%
12,051 $40.9 Million
Q3 2020

Jun 26, 2023

BUY
$3.26 - $4.73 $39,286 - $57,001
12,051 New
12,051 $40.9 Million
Q2 2020

May 24, 2024

BUY
$1.58 - $4.63 $56,680 - $166,096
35,874 New
35,874 $166 Million
Q2 2020

Jun 26, 2023

BUY
$1.58 - $4.63 $56,680 - $166,096
35,874 New
35,874 $166 Million
Q3 2019

Jul 12, 2023

BUY
$2.67 - $3.65 $87,271 - $119,303
32,686 New
32,686 $96.1 Million

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.